Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia

International Journal of Cancer

Volumn 137, Issue 3, 2015, Pages 744-749

  Sarkar, Chandrani ^a   Chakroborty, Debanjan ^a   Dasgupta, Partha Sarathi ^b   Basu, Sujit ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

5 FU; antiangiogenic drugs; colon cancer; dopamine; lung cancer; toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOPAMINE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC ANTIMETABOLITE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BONE MARROW SUPPRESSION; COLON CANCER; COLONY FORMING UNIT; CONTROLLED STUDY; HYPERTENSION; KIDNEY INJURY; LEWIS CARCINOMA; LIVER FUNCTION TEST; LIVER TOXICITY; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR VASCULARIZATION; UREA NITROGEN BLOOD LEVEL; ANIMAL; BLOOD PRESSURE; CFU COUNTING; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; HEMATOPOIESIS; HUMAN; KIDNEY; LIVER; MALE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELL LINE; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BLOOD PRESSURE; CELL LINE, TUMOR; COLONY-FORMING UNITS ASSAY; DISEASE MODELS, ANIMAL; DOPAMINE; FLUOROURACIL; HEMATOPOIESIS; HUMANS; KIDNEY; LIVER; LIVER FUNCTION TESTS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPENIA; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929518429     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29414     Document Type: Article

References (25)

1. Folkman J,. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-8.
2. Dvorak HF,. Angiogenesis: update 2005. J Thromb Haemos 2005; 3: 1835-42.
3. Lyden D, Hattori K, Dias S, et al., Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-201.
4. Sloan B, Scheinfeld NS,. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 2008; 9: 1324-35.
5. Sullivan LA, Brekken RA,. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2010; 2: 165-75.
6. Folkman J,. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
7. Davis DW, McConkey DJ, Zhang W, et al., Antiangiogenic tumor therapy. Biotechniques 2003; 34: 1048-50.
8. Chen HX, Cleck JN,. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-77.
9. Gressett SM1, Shah SR,. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009; 43: 490-501.
10. Basu S, Nagy JA, Pal S, et al., The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001; 7: 569-74.
11. Chakroborty D, Sarkar C, Mitra RB, et al., Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 2004; 10: 4349-56.
12. Sarkar C, Chakroborty D, Chowdhury UR, et al., Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res 2008; 14: 2502-10.
13. Chakroborty D, Chowdhury UR, Sarkar C, et al., Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J Clin Invest 2008; 118: 1380-9.
14. Moreno-Smith M, Lu C, Shahzad MM, et al., Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res 2011; 17: 3649-59.
15. Prewett M, Huber J, Li Y, et al., Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-18.
16. MacGregor DA, Smith TE, Prielipp RC, et al., Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 2000; 92: 338-346.
17. Sounni NE, Cimino J, Blacher S, et al., Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab 2014; 20: 280-94.
18. Chakroborty D, Sarkar C, Yu H, et al., Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci USA 2011; 108: 20730-5.
19. Facemire CS, Nixon AB, Griffiths R, et al., Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009; 54: 652-8.
20. Ezeh PC, Lauer FT, MacKenzie D, et al., Arsenite selectively inhibits mouse bone marrow lymphoid progenitor cell development in vivo and in vitro and suppresses humoral immunity in vivo. PLoS One 2014; 9: e93920
21. Hayman SR, Leung N, Grande JP, et al., VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 2012; 14: 285-94.
22. Howard SA, Krajewski KM, Thornton E, et al., Decade of molecular targeted therapy: abdominal manifestations of drug toxicities-what radiologists should know. AJR Am J Roentgenol 2012; 199: 58-64.
23. Grenon NN,. Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer. Clin J Oncol Nurs 2013; 17: 425-33.
24. Gianola FJ, Sugarbaker PH, Barofsky I, et al., Toxicity studies of adjuvant intravenous versus intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Am J Clin Oncol 1986; 9: 403-10.
25. Djazayeri K, Szilvássy Z, Peitl B, et al., Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment. Eur J Pharmacol 2005; 522: 122-9.